Stock Track | NovoCure Soars 40.48% in Pre-Market on FDA Approval for Pancreatic Cancer Treatment Device

Stock Track

Feb 12

NovoCure's stock surged 40.48% in pre-market trading on Thursday, marking a significant upward movement for the oncology company.

The dramatic rise follows the U.S. Food and Drug Administration's approval of NovoCure's Optune Pax, a wearable medical device for treating adult patients with locally advanced pancreatic cancer. The approval, announced by the company, represents the first new treatment option for this condition in nearly three decades.

The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax in combination with standard chemotherapy, compared to chemotherapy alone.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1133828447"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133828447\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133828447?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133828447","market":"hk","top_or_hot":-1,"title":"Stock Track | NovoCure Soars 40.48% in Pre-Market on FDA Approval for Pancreatic Cancer Treatment Device","media":"Stock Track","content":"<p>NovoCure's stock surged 40.48% in pre-market trading on Thursday, marking a significant upward movement for the oncology company.</p><p>The dramatic rise follows the U.S. Food and Drug Administration's approval of NovoCure's Optune Pax, a wearable medical device for treating adult patients with locally advanced pancreatic cancer. The approval, announced by the company, represents the first new treatment option for this condition in nearly three decades.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax in combination with standard chemotherapy, compared to chemotherapy alone.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Soars 40.48% in Pre-Market on FDA Approval for Pancreatic Cancer Treatment Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Soars 40.48% in Pre-Market on FDA Approval for Pancreatic Cancer Treatment Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure's stock surged 40.48% in pre-market trading on Thursday, marking a significant upward movement for the oncology company.</p><p>The dramatic rise follows the U.S. Food and Drug Administration's approval of NovoCure's Optune Pax, a wearable medical device for treating adult patients with locally advanced pancreatic cancer. The approval, announced by the company, represents the first new treatment option for this condition in nearly three decades.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax in combination with standard chemotherapy, compared to chemotherapy alone.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1133828447","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133828447","pubTimestamp":1770907923,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure's stock surged 40.48% in pre-market trading on Thursday, marking a significant upward movement for the oncology company.The dramatic rise follows the U.S. Food and Drug Administration's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"股票追踪|FDA批准胰腺癌治疗设备NovoCure盘前大涨40.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure's stock surged 40.48% in pre-market trading on Thursday, marking a significant upward movement for the oncology company.The dramatic rise follows the U.S. Food and Drug Administration's approval of NovoCure's Optune Pax, a wearable medical device for treating adult patients with locally advanced pancreatic cancer. The approval, announced by the company, represents the first new treatment option for this condition in nearly three decades.The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax in combination with standard chemotherapy, compared to chemotherapy alone.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}